Is universal screening for hepatitis C infection prior to commencing antitumour necrosis factor-α therapy necessary?

Hdl Handle:
http://hdl.handle.net/10147/336166
Title:
Is universal screening for hepatitis C infection prior to commencing antitumour necrosis factor-α therapy necessary?
Authors:
Reid, C T; De Gascun, C; Hall, W; Collins, P; Lally, A; Kirby, B
Affiliation:
Department of Dermatology, Saint Vincent's University Hospital, Elm Park, Dublin 4, Ireland.
Citation:
Reid, C.T. et al., 2013. Is universal screening for hepatitis C infection prior to commencing antitumour necrosis factor-α therapy necessary? British journal of dermatology, 169 (6) pp 1319-21
Journal:
The British journal of dermatology
Issue Date:
Dec-2013
URI:
http://hdl.handle.net/10147/336166
DOI:
10.1111/bjd.12598
PubMed ID:
24032395
Abstract:
Screening for hepatitis C virus (HCV) prior to the commencement of antitumour necrosis factor (anti-TNF)-α therapies for dermatological disease is recommended for all patients.
Item Type:
Article
Language:
en
Keywords:
SKIN CANCER; HEPATITIS C; SCREENING
MeSH:
Adolescent; Adult; Aged; Aged, 80 and over; Early Diagnosis; Female; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Immunoglobulin G; Male; Mass Screening; Middle Aged; Retrospective Studies; Skin Diseases; Tumor Necrosis Factor-alpha; Young Adult
ISSN:
1365-2133

Full metadata record

DC FieldValue Language
dc.contributor.authorReid, C Ten_GB
dc.contributor.authorDe Gascun, Cen_GB
dc.contributor.authorHall, Wen_GB
dc.contributor.authorCollins, Pen_GB
dc.contributor.authorLally, Aen_GB
dc.contributor.authorKirby, Ben_GB
dc.date.accessioned2014-11-26T14:59:32Z-
dc.date.available2014-11-26T14:59:32Z-
dc.date.issued2013-12-
dc.identifier.citationReid, C.T. et al., 2013. Is universal screening for hepatitis C infection prior to commencing antitumour necrosis factor-α therapy necessary? British journal of dermatology, 169 (6) pp 1319-21en_GB
dc.identifier.issn1365-2133-
dc.identifier.pmid24032395-
dc.identifier.doi10.1111/bjd.12598-
dc.identifier.urihttp://hdl.handle.net/10147/336166-
dc.description.abstractScreening for hepatitis C virus (HCV) prior to the commencement of antitumour necrosis factor (anti-TNF)-α therapies for dermatological disease is recommended for all patients.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to The British journal of dermatologyen_GB
dc.subjectSKIN CANCERen_GB
dc.subjectHEPATITIS Cen_GB
dc.subjectSCREENINGen_GB
dc.subject.meshAdolescent-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshEarly Diagnosis-
dc.subject.meshFemale-
dc.subject.meshHepatitis C Antibodies-
dc.subject.meshHepatitis C, Chronic-
dc.subject.meshHumans-
dc.subject.meshImmunoglobulin G-
dc.subject.meshMale-
dc.subject.meshMass Screening-
dc.subject.meshMiddle Aged-
dc.subject.meshRetrospective Studies-
dc.subject.meshSkin Diseases-
dc.subject.meshTumor Necrosis Factor-alpha-
dc.subject.meshYoung Adult-
dc.titleIs universal screening for hepatitis C infection prior to commencing antitumour necrosis factor-α therapy necessary?en_GB
dc.typeArticleen
dc.contributor.departmentDepartment of Dermatology, Saint Vincent's University Hospital, Elm Park, Dublin 4, Ireland.en_GB
dc.identifier.journalThe British journal of dermatologyen_GB
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.